Stifel Nicolaus Boosts Insmed (NASDAQ:INSM) Price Target to $67.00
Insmed (NASDAQ:INSM – Free Report) had its target price boosted by Stifel Nicolaus from $39.00 to $67.00 in a research note released on Friday morning, Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. INSM has been the topic of several other reports. UBS Group upped their price objective on […]
More Stories
Bentley Systems, Incorporated (NASDAQ:BSY) Receives $59.57 Average PT from Analysts
Shares of Bentley Systems, Incorporated (NASDAQ:BSY – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from...
Ollie’s Bargain Outlet Holdings, Inc. (NASDAQ:OLLI) Given Average Rating of “Moderate Buy” by Brokerages
Ollie’s Bargain Outlet Holdings, Inc. (NASDAQ:OLLI – Get Free Report) has received an average recommendation of “Moderate Buy” from the...
Occidental Petroleum (NYSE:OXY) PT Lowered to $65.00
Occidental Petroleum (NYSE:OXY – Get Free Report) had its price target decreased by investment analysts at BMO Capital Markets from...
Calix’s (CALX) Buy Rating Reiterated at Rosenblatt Securities
Rosenblatt Securities restated their buy rating on shares of Calix (NYSE:CALX – Free Report) in a research report sent to...
BlackRock (NYSE:BLK) Given New $1,040.00 Price Target at The Goldman Sachs Group
BlackRock (NYSE:BLK – Free Report) had its price objective increased by The Goldman Sachs Group from $960.00 to $1,040.00 in...
JPMorgan Chase & Co. Lowers ChargePoint (NYSE:CHPT) to Underweight
JPMorgan Chase & Co. downgraded shares of ChargePoint (NYSE:CHPT – Free Report) from an overweight rating to an underweight rating...